Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background Depression is common among individuals with methamphetamine (MA) use disorders. As agents that enhance serotonergic function are frequently used to treat depression, one might predict that they would be useful medications for MA dependence. However, clinical trials of serotonergic agents for MA addiction have been unsuccessful. Objective To identify factors that distinguish MA-dependent research participants who increased MA self-administration while receiving treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline from other groups of participants. Method Using a dataset from a 12-week randomized, placebo-controlled trial of sertraline (100 mg daily) for MA addiction, we identified participants who had completed at least 8 weeks of the trial (n=61 sertraline, n=68 placebo). We compared the proportions of MA-positive urine tests for weeks 8–12 of the trial for these subjects to their pre-randomization baseline, and identified those subjects who increased MA use during treatment. Using classification trees, we then assessed all data collected during the study to identify factors associated with increasing MA use during treatment with sertraline, compared to placebo. Results More subjects in the sertraline condition increased MA use during treatment (n=13) than in the placebo condition (n=5; p=0.03). Classification trees identified multiple factors from both pre-treatment and in-treatment data that were associated with increased MA use during treatment. Only elevated in-treatment craving for MA specifically characterized subjects in the sertraline group who increased their MA use. Conclusions Some MA-abusing individuals treated with SSRIs have sustained craving with an increased propensity to relapse during treatment despite psychosocial treatment interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
The nature, time course and severity of methamphetamine withdrawal
McGregor, C., Srisurapanont, M., Jittiwutikarn, J., Laobhripatr, S., Wongtan, T., & White, J. M. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01160.x · Cited by 458 · cited 1×
“, 2004) and in MA withdrawal (McGregor et al., 2005; Zorick et al., 2010), and psychosocial treatments are only partially effective (Glasner-Edwards et al.”
BackgroundPharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242 · cited 3×
“, 2006), these observations have provided justification for testing serotonergic agents as treatments for MA dependence and withdrawal syndromes (reviewed in Shoptaw et al., 2009; Karila et al., 2010).”
BackgroundInfluentialTreatment for amphetamine withdrawal
Shoptaw, S. J., Kao, U., Heinzerling, K., & Ling, W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003021.pub2 · Cited by 120
Self-citationA placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74
Galloway, G. P., Singleton, E. G., The Methamphetamine Treatment Project Corporate Authors, Anglin, M. D., Rawson, R. A., Patricia, M.-C., Joseph, B., Richard, B., Alison Hamilton, B., Cynthia, B., et al. (2008) · Substance Abuse: Research and Treatment · doi:10.4137/sart.s775 · Cited by 24
Cited by
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 498
The role of serotonin in drug use and addiction
Müller, C. P., & Homberg, J. R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.04.007 · Cited by 334
Canadian Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder
Wood, E., Bright, J., Hsu, K., Goel, N., Ross, J. W. G., Hanson, A., Teed, R., Poulin, G., Denning, B., Corace, K., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230715 · Cited by 74
“40,41 Because of the potential increase in alcohol consumption, lack of benefit in meta-analyses of randomized trials 34 and other risks (e.g., lowering seizure threshold), 42 we recommend against the use of SSRI antidepressants for the treatment of AUD, or for anxiety or depressive disorders…”
MethodHärtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-105500 · Cited by 39
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292745 · Cited by 13
“Matrix model; Methylphenidate; Matrix model + Methylphenidate; No treatment [104] • Among studies that evaluated pharmacological and behavioural interventions combined, theextent of benefits varied by outcome measure [78, 97, 104] • When comparing a behavioral intervention to a pharmacotherapy intervention, CBT tended…”
Background
Metadata
- Authors
- Zorick, T., Sugar, C. A., Hellemann, G., Shoptaw, S., & London, E. D.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 118
- Issue
- 2-3
- Pages
- 500-503
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2009400869
- Cited by
- 42
- References
- 6
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2011.04.015
- The paper
- Zorick, T., Sugar, C. A., Hellemann, G., Shoptaw, S., & London, E. D. (2011). Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2011.04.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.